Form 13-F position report

DAMORA THERAPEUTICS INC SHS (C

Reported by Kalehua Capital Management LLC

DMRA CUSIP G2646Y104 Manager CIK 0002106181

First reported at 139,000 shares this quarter.

New
% of reported 13F value 2.23% This manager · Q3 2026
Shares 139,000 Quarter-end amount reported
Reported value $2,957,920 Fair value at quarter end
Consecutive quarters held 1 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2026-09-30 2957920

Quarterly position history

How this manager's reported quarter-end position changed over time.

1 quarter
Quarterly reported position history for DAMORA THERAPEUTICS INC SHS (C held by Kalehua Capital Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 New 139,000 +139,000 (0.0%) 2.23% $2,957,920 2026-11-13

Who else reported the position

111 managers reported DAMORA THERAPEUTICS INC SHS (C for Q3 2026.

Managers reporting DAMORA THERAPEUTICS INC SHS (C in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC New 9,549,056 +9,549,056 < 0.01% $203,203,912 1 qtr
Fairmount Funds Management LLC New 8,713,000 +8,713,000 11.63% $185,412,640 1 qtr
Avoro Capital Advisors LLC New 3,783,000 +3,783,000 0.83% $80,502,240 1 qtr
VR Adviser LLC New 3,603,595 +3,603,595 3.73% $76,684,502 1 qtr
BlackRock Inc New 3,514,573 +3,514,573 < 0.01% $74,790,114 1 qtr
RA CAPITAL MANAGEMENT L P New 2,399,702 +2,399,702 0.51% $51,065,659 1 qtr
Remedium Capital Partners LLC New 2,045,473 +2,045,473 15.91% $43,527,665 1 qtr
COMMODORE CAPITAL LP New 1,939,000 +1,939,000 3.2% $41,261,920 1 qtr
Bellevue Group AG New 1,919,383 +1,919,383 0.85% $40,844,470 1 qtr
JPMorgan Chase & Co New 1,872,628 +1,872,628 < 0.01% $38,688,495 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
139,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.